Substituted isoindoline-1,3-dione derivatives
AssigneeConcert Pharmaceuticals, Inc.
InventorJulie F. Liu
Life of this patent
Estimating the term…
Abstract
This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast.
Claims23
1-19. (canceled)
A method of inhibiting PDE4 in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from CH3, CH2D, CHD2, and CD3
- R2 is methyl or CD3;
- R3 is CD3;
- R4 is an ethyl group substituted with zero to five deuterium, or is a cyclopentyl group substituted with zero to nine deuterium;
- X is C═O;
- each of Y1a, Y1b, Y2, Y3, Y4, Y5, Y7 and Y8 is independently selected from H and D;
- and
- Y6 is selected from Cl, H, and D.
A method of reducing TNF-α levels in a subject in need thereof, comprising administering to the subject an effective amount of a compound Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from CH3, CH2D, CHD2, and CD3;
- R2 is methyl or CD3;
- R3 is CD3;
- R4 is an ethyl group substituted with zero to five deuterium, or is a cyclopentyl group substituted with zero to nine deuterium;
- X is C═O;
- each of Y1a, Y1b, Y2, Y3, Y4, Y5, Y7, and Y8 is independently selected from H and D;
- and
- Y6 is selected from Cl, H, and D.
A method of treating a disease selected from the group consisting of septic shock, sepsis, endotoxic shock, hemodynamic shock and sepsis syndrome, post ischemic reperfusion injury, malaria, mycobacterial infection, meningitis, psoriasis, sarcoidosis, psoriatic arthritis, Behçet's Disease, prurigo nodularis, lupus, uveitis, congestive heart failure, fibrotic disease, cachexia, graft rejection, cancer, autoimmune disease, opportunistic infections in AIDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, other arthritic conditions, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythrematosis, ENL in leprosy, radiation damage, hyperoxic alveolar injury, undesirable angiogenesis, inflammatory disease, arthritis, inflammatory bowel disease, aphthous ulcers, asthma, adult respiratory distress syndrome, and AIDS, in a patient in need thereof comprising administering to the patient an effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from CH3, CH2D, CHD2, and CD3;
- R2 is methyl or CD3;
- R3 is CD3;
- R4 is an ethyl group substituted with zero to five deuterium, or is a cyclopentyl group substituted with zero to nine deuterium;
- X is C═O;
- each of Y1a, Y1b, Y2, Y3, Y4, Y5, Y7 and Y8 is independently selected from H and D;
- and
- Y6 is selected from Cl, H, and D.
Dependencies are inferred from the claim text.